Placental Tissue Matrix Skye Biologics PX50®

> Case Report July 31, 2016

Shawn Tierney, DC, RSMK Musculoskeletal Sonologist Carol Hanselman, RNP Rome Walter, DO

Diagnosis

Low Back Pain, Degeneration of the right L4-L5 and L5-S1 lumbar facet joints

Intro

On November 4, 2015, a 51-year-old female presented to the clinic with over 10 years of progressively worsening low back pain. She had lost two jobs in the past because her back pain was unbearable with prolonged sitting. She takes multiple narcotic pain-relieving medications in order to sleep and function in her current fulltime profession.

Patient was examined by Shawn Tierney, DC, RMSK Musculoskeletal Sonologist, using a GE R6 B-mode ultrasound using 8 to 13MHz high frequency GE 12L linear transducer and a 2 to 5.3MHz 4C curvilinear transducer. His ultrasound exam revealed hypermobility and tenderness to palpation of the right L4-L5 and right L5-S1 lumbar facet joint.

Treatment

0.5 cc .5% Ropivacaine was mixed with 0.5 cc Skye Biologics Placental Tissue Matrix Allograft, PX50[®], and injected into the right facet joints of L4-L5 and L5-S1 in the patient's low back. The goal was to provide sustaining regeneration to the patient's low back and to prevent further lumbar facet joint degeneration.

Follow-up

Within five minutes of the injection, patient reported 100% of her lower back pain was relieved. On January 18, 2016, ten weeks after the injection, she said her lower back was much better. She reported that her mid-back was now the most significant area of pain. Patient was reevaluated on July 29, 2016, and reported that her low back was markedly improved, and that she now wanted to receive an additional PX50[®] treatment on the joints of her thoracic spine at her next appointment.

Figure 1. Reduction in Self-Reported Pain on a 1-10 Scale, before and after PTM Placental Tissue Matrix

Level of Pain	Pre- PX50®	Post- PX50®
	8/8/16	10/20/16
Average Pain	7	2
% Reduction in Pain	71%	